Association between Paxlovid and mortality in severe COVID-19 patients: a retrospective cohort study
The Journal of Infection in Developing Countries · 30.06.2026 · 20 (06) · 896-903
DOI: 10.3855/jidc.21811 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Journal of Infection in Developing Countries, online erschienen am 30.06.2026. Verfasst von Bin Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Zhuzhou Central Hospital, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central So…. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Drug Treatment. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
With limited research on the clinical effectiveness of Paxlovid for hospitalized patients with severe COVID-19, this study aims to assess its impact on clinical outcomes, providing essential insights for patient care. Methodology: We collected consecutive data from SARS-CoV-2-infected patients at four hospitals between December 2022 and July 2023. We compared patient characteristics, clinical parameters, and treatment regimens between the Paxlovid and control groups. Analyses included crude, multivariable, doubly robust, and propensity score methods to evaluate Paxlovid's impact on 28-day mortality and to identify subgroup interactions.
Results
Of 574 patients treated with Paxlovid, 10.3% died within 28 days, versus 29.9% of 645 untreated patients. Unadjusted analysis showed a significant Paxlovid-associated reduction in 28-day mortality (OR 0.268, 95% CI 0.195-0.369; p < 0.001), sustained after adjustment (adjusted OR 0.298, 95% CI 0.198-0.447; p < 0.001). Paxlovid significantly decreased mortality in patients with infection durations ≤ 5 days (OR 0.401, 95% CI 0.227-0.707, p < 0.001) and > 5 days (OR 0.540, 95% CI 0.309-0.946, p < 0.001). Hospital stays were longer with Paxlovid (median 11 vs. 10 days, p = 0.001), with no significant effect on ICU admission rates.
Conclusions
Our findings suggest that Paxlovid significantly reduces 28-day mortality in severe COVID-19 patients, irrespective of infection duration over 5 days.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Zhuzhou Central Hospital, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, No.116, Changjiang South Road, Tianyuan District, Zhuz…
- Department of Scientific Research, Zhuzhou Central Hospital, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, 412007, Hunan, China.
- Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, No.1, Youyi Road, Yuzhong, Chongqing, 400016, China.
- Department of General Practice, People's Hospital of Chongqing Hechuan, Chongqing 401520, China.
- Department of Endocrinology and Metabolism, Chengdu First People's Hospital, No.18, Wanxiang North Road, High-tech Zone, Chengdu, Sichuan, 610000, China.
- Digestive System Department, Chengdu Second People's Hospital, jinjiang District, Chengdu, Sichuan, 610017, China.
Zitieren
APA
Liu, B., Xie, B., Jiang, L., Xia, H., Zhu, C., Hu, J., Cai, J., Zhang, Y., Yang, M., & Liang, Y. (2026). Association between Paxlovid and mortality in severe COVID-19 patients: a retrospective cohort study. The Journal of Infection in Developing Countries, 20(06), 896-903. https://doi.org/10.3855/jidc.21811
Vancouver
Liu B, Xie B, Jiang L, Xia H, Zhu C, Hu J, et al. Association between Paxlovid and mortality in severe COVID-19 patients: a retrospective cohort study. The Journal of Infection in Developing Countries. 2026;20(06):896-903. doi:10.3855/jidc.21811
BibTeX
@article{Liu2026,
author = {Liu, Bin and Xie, Bo and Jiang, Li and Xia, Hongli and Zhu, Chunmei and Hu, Jing and Cai, Jing and Zhang, Yan and Yang, Mingjin and Liang, Yanchao},
title = {Association between Paxlovid and mortality in severe COVID-19 patients: a retrospective cohort study},
journal = {The Journal of Infection in Developing Countries},
year = {2026},
volume = {20},
number = {06},
pages = {896--903},
doi = {10.3855/jidc.21811}
}
EUVIMED